Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0CI4E
|
||||
| Former ID |
DCL000592
|
||||
| Drug Name |
Pertuzumab
|
||||
| Synonyms |
Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Approved | [1], [2] | ||
| Company |
Roche; Genentech
|
||||
| CAS Number |
CAS 145040-37-5
|
||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L01XC13
|
||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-2 | Target Info | Inhibitor | [3], [4] | |
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Prostate cancer | |||||
| Bladder cancer | |||||
| Non-small cell lung cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| ErbB2/ErbB3 signaling events | |||||
| ErbB receptor signaling network | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| PathWhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
| Reactome | SHC1 events in ERBB2 signaling | ||||
| PLCG1 events in ERBB2 signaling | |||||
| PIP3 activates AKT signaling | |||||
| GRB2 events in ERBB2 signaling | |||||
| PI3K events in ERBB2 signaling | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| Sema4D induced cell migration and growth-cone collapse | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| ErbB Signaling Pathway | |||||
| EGF/EGFR Signaling Pathway | |||||
| Focal Adhesion | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Bladder Cancer | |||||
| Signaling by ERBB2 | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Leptin signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Semaphorin interactions | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046). | ||||
| REF 2 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. | ||||
| REF 3 | Pertuzumab. Drugs Fut 2008, 33(2): 123 ISSN 0377-8282. | ||||
| REF 4 | Clinical pipeline report, company report or official report of Roche (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.